Search Results for 'Tavr'

Tavr published presentations and documents on DocSlides.

The DEFLECT III Trial:

pasty-toler
35 Slides

A Prospective Randomized Evaluation of the . TriG...

Balloon-Expandable TAVR in Inoperable Patients With Severe

celsa-spraggs
71 Slides

The PARTNER Trial Cohort B 2-Year Results. The in...

Balloon-Expandable TAVR in Inoperable Patients With Severe

tatiana-dople
66 Slides

The PARTNER Trial Cohort B 2-Year Results. The in...

1 Safety and Quality in the Cardiothoracic

faustina-dinatale
17 Slides

Operating Room. Engy Hanna. , MD . Director, Card...

Mitigating Stroke Risk in TAVR:

celsa-spraggs
0 Slides

Important Considerations . as TAVR Moves to . Low...

Structural Heart Live Cases

cheryl-pisano
0 Slides

Supported by:. Medtronic inc. Bard Inc. Teru...

Adnan H. Siddiqui, MD , PhD

trish-goza
0 Slides

Professor & Vice-Chairman Department of Neuro...

TAVR and the Risk of Thrombosis

briana-ranney
0 Slides

Program Goals. Thromboembolic Risk Associated Wit...

Anticoagulants in Interventional Cardiology:

trish-goza
0 Slides

Overview of Anticoagulation in . Interventional C...

The Process of TAVR Development

kinohear
17 Slides

Stanton J Rowe. CEO. NXT Biomedical. I, Stanton Ro...

General anesthesia versusconscious sedation intranscatheter aortic val

molly
5 Slides

10.4172/Interventional-Cardiology.1000623

“TAVR: Transcatheter Treatment of Aortic Stenosis Comes of Age

priscilla
23 Slides

”. Muhammad Raza, MD, FACC, FSCAI, RPVI.. Interv...

Leadership Project: Transcatheter

elena
11 Slides

Aortic Valve Replacement Resource Manual. Molina A...

Critical Review of the Evidence:

emily
22 Slides

TAVR in Low-Risk Bicuspid in Patients. John Forres...

Adapting to Change in Structural Heart Disease Training

priscilla
15 Slides

Michael Mack, MD. Baylor Scott & White Health....

Edwards 2017 Healthcare Leadership Series

isabella2
19 Slides

Shilpa Shelton, MBA. Program Director, . Bluhm. C...

Principles of Reimbursement

Pirateking
21 Slides

“Back to the basics” – Coding Documentation,...

5-Year Clinical and Echocardiographic Outcomes from the Randomized SURTAVI Trial

SocialButterfly
24 Slides

Nicolas M. Van Mieghem, MD, PhD. For the SURTAVI T...

Primary Results From the EvolutLow Risk Bicuspid StudyBasel Ramlawi M

candy
27 Slides

1 Disclosure Statement of Financial InterestsWithi...

Do We Have Enough TAVR Centers?

amelia
23 Slides

A Heart Team Perspective. Interventional cardiolog...

Valve Reoperation after Native and Valve-in-Valve Transcatheter Aortic Valve Replacement: A Statewi

sophia2
15 Slides

Shinichi Fukuhara, MD . (. 1,4,5). , Stephane Leun...

Howard C. Herrmann, MD, FACC, MSCAI

yvonne
29 Slides

John . Bryfogle. Professor of Cardiovascular Medi...

Mind the gap: avoiding paravalvular leak using computer simulation in bicuspid transcatheter aortic

brooke
13 Slides

EHJ-CR-D-22-00342. July 2022. Introduction. EHJ-CR...

CRITICAL AORTIC STENOSIS: ECMO USED IN MORE WAYS THAN ONE

eddey
11 Slides

Gregory Condos, MD, LCDR, MC, USN; Katherine Rees;...

Dual Anti-Platelet Therapy After TAVR?

salem
13 Slides

By: Cole Smith PharmD Candidate 2021. University o...

Two-year Clinical and Echocardiographic Outcomes from the PARTNER 3 Low-risk Randomized Trial

braylen673
26 Slides

Low-risk Randomized Trial. Michael J. Mack, . MD &...

Primary Results From the Evolut Low Risk Bicuspid Study

cody
27 Slides

Evolut. Low Risk Bicuspid Study. Basel Ramlawi, M...